Cargando…

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions

Three phase II randomized trials evaluated the safety/immunogenicity of two formulations of live-attenuated tetravalent dengue virus (TDEN) vaccine in dengue-endemic (Puerto Rico, Thailand) and non-endemic (US) regions (NCT00350337/NCT00370682/NCT00468858). We describe cell-mediated immune (CMI) res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moris, Philippe, Bauer, Kristen M., Currier, Jeffrey R., Friberg, Heather, Eckels, Kenneth H., Esquilin, Ines O., Gibbons, Robert V., Innis, Bruce L., Jarman, Richard G., Simasathien, Sriluck, Sun, Peifang, Thomas, Stephen J., Watanaveeradej, Veerachai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773406/ https://www.ncbi.nlm.nih.gov/pubmed/30829100 http://dx.doi.org/10.1080/21645515.2019.1581536

Ejemplares similares

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
por: Watanaveeradej, Veerachai, et al.
Publicado: (2016)

Safety and Immunogenicity of a Rederived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults Living in Thailand: A Randomized Trial
por: Watanaveeradej, Veerachai, et al.
Publicado: (2014)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults
por: Friberg, Heather, et al.
Publicado: (2022)

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults
por: LeFevre, Inge, et al.
Publicado: (2023)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques
por: Fernandez, Stefan, et al.
Publicado: (2015)

Safety and Immunogenicity of an AS03(B)-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study
por: Lin, Leyi, et al.
Publicado: (2020)

Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States
por: Schmidt, Alexander C., et al.
Publicado: (2017)

Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico
por: Diaz, Clemente, et al.
Publicado: (2018)

Influenza Vaccine Effectiveness in the Tropics: Moderate Protection in a Case Test-Negative Analysis of a Hospital-Based Surveillance Population in Bangkok between August 2009 and January 2013
por: Levy, Jens W., et al.
Publicado: (2015)

Threat of Dengue to Blood Safety in Dengue-Endemic Countries
por: Wilder-Smith, Annelies, et al.
Publicado: (2009)

Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine
por: DeMaso, Christina R, et al.
Publicado: (2022)

Transplacental Chikungunya Virus Antibody Kinetics, Thailand
por: Watanaveeradej, Veerachai, et al.
Publicado: (2006)

A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
por: Nivarthi, Usha K., et al.
Publicado: (2021)

A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico
por: Bauer, Kristen, et al.
Publicado: (2015)

Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
por: Dayan, Gustavo H, et al.
Publicado: (2014)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)
por: White, Laura J., et al.
Publicado: (2021)

A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults
por: Thomas, Stephen J., et al.
Publicado: (2013)

Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003
por: Tu, Huy A., et al.
Publicado: (2020)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Metagenomics Study of Viral Pathogens in Undiagnosed Respiratory Specimens and Identification of Human Enteroviruses at a Thailand Hospital
por: Zhou, Yanfei, et al.
Publicado: (2016)

Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
por: Waickman, Adam T., et al.
Publicado: (2019)

Dengue Endemicity, Force of Infection, and Variation in Transmission Intensity in 13 Endemic Countries
por: Nealon, Joshua, et al.
Publicado: (2020)

Value of routine dengue diagnosis in endemic countries
por: Ayukekbong, James Ayukepi, et al.
Publicado: (2017)

Dengue: 30 years of cases in an endemic area
por: Monteiro, Daniela Cristina Sensato, et al.
Publicado: (2019)

Heterogeneity of dengue transmission in an endemic area of Colombia
por: Estupiñán Cárdenas, María Isabel, et al.
Publicado: (2020)

Acute retroviral syndrome mimincs dengue in Singapore, a dengue endemic country
por: Tan, JH, et al.
Publicado: (2012)

Case report: Weil’s disease with multiple organ failure in a child living in dengue endemic area
por: Lokida, Dewi, et al.
Publicado: (2016)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate
por: Patel, Sanjay S, et al.
Publicado: (2022)

Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study
por: Sirivichayakul, Chukiat, et al.
Publicado: (2020)

To alert coinfection of COVID-19 and dengue virus in developing countries in the dengue-endemic area
por: Wu, Di, et al.
Publicado: (2020)

Dengue pre-vaccination screening test evaluation for the use of dengue vaccine in an endemic area
por: Limothai, Umaporn, et al.
Publicado: (2021)

The Impact of the Newly Licensed Dengue Vaccine in Endemic Countries
por: Aguiar, Maíra, et al.
Publicado: (2016)

Diagnosis of COVID-19 in a Dengue-Endemic Area
por: Lokida, Dewi, et al.
Publicado: (2020)

Clinical and laboratory predictors of influenza infection among individuals with influenza-like illness presenting to an urban Thai hospital over a five-year period
por: Anderson, Kathryn B., et al.
Publicado: (2018)

Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates
por: Strouts, Fiona R., et al.
Publicado: (2016)

Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation()
por: Bentsi-Enchill, Adwoa D., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6jg3ts0bruvh6rf2nb9obi69nj